Neurocrine Biosciences, Inc. (NBIX)
168.52
+4.34
(+2.64%)
USD |
NASDAQ |
Jun 26, 16:00
166.00
-2.52
(-1.50%)
After-Hours: 20:00
Neurocrine Biosciences Cash from Operations (TTM) : 863.70M for March 31, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| March 31, 2026 | 863.70M |
| December 31, 2025 | 782.70M |
| September 30, 2025 | 636.80M |
| June 30, 2025 | 567.30M |
| March 31, 2025 | 529.90M |
| December 31, 2024 | 595.40M |
| September 30, 2024 | 476.40M |
| June 30, 2024 | 530.40M |
| March 31, 2024 | 645.40M |
| December 31, 2023 | 389.90M |
| September 30, 2023 | 409.40M |
| June 30, 2023 | 296.20M |
| March 31, 2023 | 254.70M |
| December 31, 2022 | 339.40M |
| September 30, 2022 | 200.60M |
| June 30, 2022 | 163.60M |
| March 31, 2022 | 128.70M |
| December 31, 2021 | 256.50M |
| September 30, 2021 | 341.20M |
| June 30, 2021 | 261.90M |
| March 31, 2021 | 277.60M |
| December 31, 2020 | 228.50M |
| September 30, 2020 | 242.15M |
| June 30, 2020 | 357.48M |
| March 31, 2020 | 302.74M |
| Date | Value |
|---|---|
| December 31, 2019 | 152.05M |
| September 30, 2019 | 99.96M |
| June 30, 2019 | 71.05M |
| March 31, 2019 | 27.36M |
| December 31, 2018 | 101.36M |
| September 30, 2018 | 91.48M |
| June 30, 2018 | 13.26M |
| March 31, 2018 | -55.46M |
| December 31, 2017 | -94.33M |
| September 30, 2017 | -166.53M |
| June 30, 2017 | -188.23M |
| March 31, 2017 | -154.33M |
| December 31, 2016 | -106.18M |
| September 30, 2016 | -89.76M |
| June 30, 2016 | -77.32M |
| March 31, 2016 | -49.02M |
| December 31, 2015 | -38.00M |
| September 30, 2015 | -38.10M |
| June 30, 2015 | -31.63M |
| March 31, 2015 | -55.56M |
| December 31, 2014 | -47.14M |
| September 30, 2014 | -42.71M |
| June 30, 2014 | -41.39M |
| March 31, 2014 | -41.29M |
| December 31, 2013 | -29.61M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Biogen, Inc. | 2.591B |
| Amgen, Inc. | 10.76B |
| Iovance Biotherapeutics, Inc. | -270.79M |
| Voyager Therapeutics, Inc. | -127.99M |
| Incyte Corp. | 1.517B |